- October 6, 2020
12:30 PM - 5:00 PM ET
On October 6, 2020, FDA is hosting a virtual public meeting on Patient-Focused Drug Development for Stimulant Use Disorder. This meeting will provide FDA the opportunity to obtain input from individuals who are struggling or have struggled with the use of cocaine, crystal meth, methamphetamine, or misuse of prescription stimulants such as Adderall or Ritalin. Family members, advocates, caregivers and other stakeholders are encouraged to participate and share their views on the condition. In particular, FDA is interested in hearing perspectives on the:
- Health effects and daily impacts of their condition
- Impact (if any) of opioid and polysubstance use on their condition
- Treatment goals
- Decision factors considered when seeking out or selecting a treatment
This website will be updated as meeting materials are developed. This event is FREE.
October 6, 2020
12:30 PM – 5:00 PM ET
SUBMIT A COMMENT TO THE DOCKET
We encourage participants to submit written comments to the docket by December 7, 2020: https://www.regulations.gov/document?D=FDA-2020-N-0259-0005 or go to https://www.regulations.gov/ and search for: FDA-2020-N-0259.